Supernus Pharmaceuticals | Innovating CNS Treatments
Supernus, a biopharmaceutical company, develops CNS disease treatments. Transforming patient care with cutting-edge therapies and strategic partnerships.
U.S. FDA approves Supernus' drug-device combination for …
6 days ago · The drug-device combo, which Supernus acquired through a $530-million deal, opens new tab in 2020, continuously delivers the drug apomorphine under the skin, providing a more convenient method of ...
About Us - Supernus
At Supernus, we develop innovative products that help treat neurological and psychiatric conditions. It's about more than science and research, though. It's about the real impact these products have on people by helping to improve their health.
Supernus Announces FDA Approval of ONAPGO™ (apomorphine …
6 days ago · Supernus Pharmaceuticals, Inc. ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease. ONAPGO ...
Supernus CNS Products | Neurology & Psychiatry Conditions
At Supernus, we create innovative products to treat neurology and psychiatry conditions, focusing on their real impact in improving people's health.
FDA Approves Apomorphine Infusion Device SPN-830 as New …
Feb 4, 2025 · Nearly 4 and a half years since its original submission, the FDA has approved Supernus Pharmaceuticals’ investigational agent SPN-830 (Onapgo) as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson disease (PD).
Supernus Pharmaceuticals Announces FDA Approval of ONAPGO, …
6 days ago · Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Supernus wins FDA approval for Parkinson’s pump on fourth try
5 days ago · Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of Parkinson’s disease. Supernus’ regulatory path for Onapgo has been marked by multiple setbacks over nearly five years, with the Food and Drug Administration (FDA) rejecting three prior applications before securing approval.
subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson s disease (PD). Supernus will make ONAPGO available in the second quarter of 2025 with a support team of experts, including a robust nurse education program, and access support at launch.
Supernus Announces FDA Approval of ONAPGO ... - Markets Insider
6 days ago · Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.